AGCバイオロジクス(ハイデルベルグ)有限会社

AGC Biologics announced the launch of AGCellerate, a new program designed to deliver effective IND-ready GMP material for biopharmaceutical developers, offering guaranteed amounts at fixed timelines and costs. The program supports biologics projects using monoclonal antibodies (mAbs), lentiviral vectors, adeno-associated vectors, and Plasmid DNA (pDNA). The AGCellerate mAb program offers 1.0 KG of clinical ready drug substance in 11 months, supported by AGC Biologics’ proprietary Chef-1™ platform.

AGC Biologics' white paper in collaboration with GORE discusses the development and demonstration of a high-productivity, fully single-use downstream processing platform for monoclonal antibody (mAb) production at an industrial scale, focusing on the use of Gore 1 Liter Devices to culture approximately 500 L of antibody harvest and purify it, demonstrating the feasibility of a full 2000 L batch.

MAb-solutely! コストの高いレジンに代わる新しい選択肢が抗体を臨床マイルストーンへ導く

AGC Biologics、ATUMと提携し、細胞株開発のタイムラインを加速。新サービスは単クローン抗体、多特異性および複雑分子の薬剤開発者に柔軟で強力な細胞株開発オプションを提供。シアトル – 2025年12月2日。薬剤開発者が価格を下げ、市場投入時間を短縮する圧力に直面する中、グローバル製薬委託開発・製造組織AGC Biologicsは、ATUMと提携してLeap-In Transposase発現プラットフォームを統合し、Cell Line Development Center of Excellenceを拡大。今回の提携により、収率を向上させ、臨床試験への道を大幅に短縮する技術が提供され、市場のスピードと効率のニーズに直接応える。

Published a thought leadership blog titled 'How Modular Bioreactors Are Shortening the Path from IND to Commercial Launch' on April 27, 2026.

AGC Biologics was involved in further developing a bispecific drug candidate for Novelty Nobility.

AGC Biologics joined the Orphan Therapeutics Accelerator’s Clinical Development Network as a manufacturing partner to advance cell and gene therapies for ultra-rare diseases.

AGC Biologics announced to manufacture Teikoku Seiyaku's rhMMP-7 drug substance.

Published a thought leadership blog titled 'Quality From the Start: A Practical Approach to Regulatory Compliance and Market Success' on May 27, 2026.

AGC Biologics participated in the BIO International Convention held at the San Diego Convention Center in San Diego, CA from June 22-25, 2026, and was present at Booth 4707.

AGC Biologics featured the new AGCellerate platform for mAbs at BIO International in Boston, held at Booth #3365 - 3369 in the Contract Services Zone, from June 22-25, 2026.

AGC Biologics、パイラミッド・ファーマサービスとの戦略的パートナーシップにより米国でフィル・フィニッシュを拡大

AGC Biologics、横浜サイトで数億ドル規模の商業製造契約を獲得

Flen Health、次世代創傷治療用再組換え酵素製造をAGC Biologicsに委託

BIO Europe Fall - ブース8-36でお会いしましょう - 日時：2026年11月9-11日 - 場所：コロンビア・メッセ、ケルン、ドイツ

BIO Europe Fall